
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. has raised its fiscal year 2026 earnings per share estimate to $(4.17), a substantial improvement from the previous estimate of $(8.63), indicating a positive shift in financial expectations. The anticipated approval of the MyoVista device, along with the rollout of the MyoVista Insights cloud software platform and the expected FDA approval of its first diagnostic algorithm by the first half of 2026, highlights the company's potential for significant market expansion. The company is affirming its regulatory timing, suggesting that it is well-positioned for large-scale opportunities in the emerging AI-driven cardiac screening market.
Bears say
HeartSciences Inc faces significant risks that negatively impact its stock outlook, including liquidity challenges, the inability of product candidates to prove safety and efficacy in clinical trials, and hurdles in gaining necessary regulatory approvals. Additionally, the company's projected revenue for FY2026 has been drastically reduced from $1.2 million to $0.1 million due to delays associated with FDA processes, indicating potential setbacks in commercialization. Compounding these issues are broader concerns related to market competition and fluctuating investor sentiment towards healthcare investments, which may further inhibit financial stability and growth prospects.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares